143 related articles for article (PubMed ID: 8162583)
1. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.
Achbarou A; Kaiser S; Tremblay G; Ste-Marie LG; Brodt P; Goltzman D; Rabbani SA
Cancer Res; 1994 May; 54(9):2372-7. PubMed ID: 8162583
[TBL] [Abstract][Full Text] [Related]
2. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer.
Shukeir N; Arakelian A; Kadhim S; Garde S; Rabbani SA
Cancer Res; 2003 May; 63(9):2072-8. PubMed ID: 12727822
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells.
Powell CT; Gschwend JE; Fair WR; Brittis NJ; Stec D; Huryk R
Cancer Res; 1996 Sep; 56(18):4137-41. PubMed ID: 8797581
[TBL] [Abstract][Full Text] [Related]
4. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Rabbani SA; Gladu J
Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
[TBL] [Abstract][Full Text] [Related]
5. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia.
Shukeir N; Arakelian A; Chen G; Garde S; Ruiz M; Panchal C; Rabbani SA
Cancer Res; 2004 Aug; 64(15):5370-7. PubMed ID: 15289344
[TBL] [Abstract][Full Text] [Related]
6. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo.
Rabbani SA; Harakidas P; Bowlin T; Attardo G
Cancer Res; 1998 Aug; 58(15):3461-5. PubMed ID: 9699681
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer.
Koutsilieris M; Sourla A; Pelletier G; Doillon CJ
J Bone Miner Res; 1994 Nov; 9(11):1823-32. PubMed ID: 7863832
[TBL] [Abstract][Full Text] [Related]
8. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
9. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
Soff GA; Sanderowitz J; Gately S; Verrusio E; Weiss I; Brem S; Kwaan HC
J Clin Invest; 1995 Dec; 96(6):2593-600. PubMed ID: 8675623
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.
Inoue K; Slaton JW; Eve BY; Kim SJ; Perrotte P; Balbay MD; Yano S; Bar-Eli M; Radinsky R; Pettaway CA; Dinney CP
Clin Cancer Res; 2000 May; 6(5):2104-19. PubMed ID: 10815938
[TBL] [Abstract][Full Text] [Related]
11. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo.
Rabbani SA; Gladu J; Harakidas P; Jamison B; Goltzman D
Int J Cancer; 1999 Jan; 80(2):257-64. PubMed ID: 9935208
[TBL] [Abstract][Full Text] [Related]
12. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells.
Haq M; Goltzman D; Tremblay G; Brodt P
Cancer Res; 1992 Sep; 52(17):4613-9. PubMed ID: 1511429
[TBL] [Abstract][Full Text] [Related]
13. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).
Rabbani SA; Harakidas P; Davidson DJ; Henkin J; Mazar AP
Int J Cancer; 1995 Dec; 63(6):840-5. PubMed ID: 8847143
[TBL] [Abstract][Full Text] [Related]
14. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
18. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
20. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase.
Rabbani SA; Gladu J; Mazar AP; Henkin J; Goltzman D
J Cell Physiol; 1997 Aug; 172(2):137-45. PubMed ID: 9258335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
